Corpus Intelligence IC Memo — CLEARSKY REHAB HOSPITAL ROSEPINE 2026-04-26 12:47 UTC
IC Memo — CLEARSKY REHAB HOSPITAL ROSEPINE
Investment Committee Memorandum | LA | 20 beds | Grade C | EBITDA uplift $446K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CLEARSKY REHAB HOSPITAL ROSEPINE

CCN 193050 | VERNON PARISH, LA | 20 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

CLEARSKY REHAB HOSPITAL ROSEPINE is a 20-bed rural/critical access in VERNON PARISH, LA with $5.9M in net patient revenue and a 5.9% operating margin. The hospital serves a payer mix of 77.9% Medicare, 0.9% Medicaid, and 21.1% commercial.

Thesis: Turnaround. Our ML models identify $446K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 5.9% to 13.4% (+754bps).

Net Revenue HCRIS$5.9M
Current EBITDA COMPUTED$348K
Operating Margin COMPUTED5.9%
Occupancy HCRIS52.2%
Revenue / Bed COMPUTED$295K
Net-to-Gross HCRIS65.7%
Distress Probability ML54.0%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
126
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of 5.9% places it above the state median. Among 126 size-comparable peers (10-40 beds), the median margin is -2.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (10-40), prioritizing same-state peers. 126 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CLEARSKY REHAB HOSPITAL ROSEPI (Target)LA20$5.9M5.9%
SPECIALISTS HOSPITAL OF SHREVELA15$79.1M21.3%
OCHSNER BAYOU LLCLA25$76.5M-0.9%
OUR LADY OF THE ANGELS HOSPITALA36$76.2M-4.9%
CENTRAL LOUISIANA SURGICAL HOSLA24$69.1M7.7%
ST. CHARLES PARISH HOSPITALLA27$64.0M-5.1%
AVALALA21$64.0M7.4%
BYRD REGIONAL HOSPITALLA39$61.1M2.5%
THE SPINE HOSPITAL OF LOUISIANLA23$57.4M35.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $446K (754bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$124K+210bp18mo
Denial Rate Reduction12.0%6.5%$122K+206bp12mo
Cost to Collect4.5%2.5%$118K+200bp12mo
A/R Days Reduction5200.0%3800.0%$72K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+16bp6mo

5. EBITDA Bridge

Net Collection Rate
$124K
Denial Rate Reduction
$122K
Cost to Collect
$118K
A/R Days Reduction
$72K
Clean Claim Rate
$10K
Total EBITDA Uplift$446K
Current EBITDA$348K
+ RCM Uplift+$446K
Pro Forma EBITDA$793K
Current Margin5.9%
Pro Forma Margin13.4%
WC Released (1x)$227K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$535K$6.7M12.62x66.0%
Base (11x exit)10.0x11.0x$535K$7.6M14.21x70.0%
Bull Case9.0x11.0x$481K$9.2M19.20x80.6%
Bull (12x exit)9.0x12.0x$481K$10.2M21.24x84.3%
Bear Case11.0x10.0x$588K$4.3M7.39x49.2%
Bear (11x exit)11.0x11.0x$588K$5.0M8.45x53.2%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumHeavy Medicare dependenceMedicare comprises 77.9% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement
HighElevated distress probabilityModel estimates 54.0% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 126 hospitals with 10-40 beds
  • Same-state prioritization (n=127)
  • Comp margins: P25=-15.8% / P50=-2.9% / P75=7.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.